share_log

Ascendiant Capital Initiates Coverage On NRX Pharmaceuticals With Buy Rating, Announces Price Target of $4

Benzinga Real-time News ·  Nov 9, 2022 06:22

Ascendiant Capital analyst Edward Woo initiates coverage on NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy rating and announces Price Target of $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment